Pharmaceutical

RegenxBio touts positive data for rare disease drug RGX-121

RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time gene therapy treatment for Hunter syndrome.

Sep 4, 2024 - 04:00
RegenxBio touts positive data for rare disease drug RGX-121
RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time gene therapy treatment for Hunter syndrome.
Read the original article

Tags:

Previous Article

FDA grants fast track status to Innovent’s IBI363 for melanoma

Next Article

Ocaliva approval in Europe withdrawn following data re-assessment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Phase I/II trial begins for SpyGlass intraocular drug delivery implant

Phase I/II trial begins for SpyGlass intraocular drug d...

Oct 31, 2023

Prometheus’ PRA023 could address an immediate need in Crohn’s Disease treatment

Prometheus’ PRA023 could address an immediate need in C...

Mar 23, 2023

STAT+: How are insurers handling the Alzheimer’s drug Leqembi and related scans?

STAT+: How are insurers handling the Alzheimer’s drug L...

Jul 12, 2023